Rethinking Vasopressin: New Insights into Vasopressin Signaling and Its Implications

Watts, Jason A.; Arroyo, Juan Pablo

doi:10.34067/kid.0000000000000194

Cited by 2 publications

(1 citation statement)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vasopressin, or arginine vasopressin (AVP), or antidiuretic hormone (ADH), is a nonapeptide synthesized as a prohormone, primarily in hypothalamic neurons. It plays a key role in the control of blood pressure, osmotic balance, kidney function, and sodium homeostasis [151,152]. Three types of AVP receptors have been identified: V1a, V1b (also called V3), and V2.…”

Section: Vasopressin and Terlipressinmentioning

confidence: 99%

An Update on Pharmacologic Management of Neonatal Hypotension: When, Why, and Which Medication

Agakidou,

Chatziioannidis,

Kontou

et al. 2024

Children

View full text Add to dashboard Cite

Anti-hypotensive treatment, which includes dopamine, dobutamine, epinephrine, norepinephrine, milrinone, vasopressin, terlipressin, levosimendan, and glucocorticoids, is a long-established intervention in neonates with arterial hypotension (AH). However, there are still gaps in knowledge and issues that need clarification. The main questions and challenges that neonatologists face relate to the reference ranges of arterial blood pressure in presumably healthy neonates in relation to gestational and postnatal age; the arterial blood pressure level that potentially affects perfusion of critical organs; the incorporation of targeted echocardiography and near-infrared spectroscopy for assessing heart function and cerebral perfusion in clinical practice; the indication, timing, and choice of medication for each individual patient; the limited randomized clinical trials in neonates with sometimes conflicting results; and the sparse data regarding the potential effect of early hypotension or anti-hypotensive medications on long-term neurodevelopment. In this review, after a short review of AH definitions used in neonates and existing data on pathophysiology of AH, we discuss currently available data on pharmacokinetic and hemodynamic effects, as well as the effectiveness and safety of anti-hypotensive medications in neonates. In addition, data on the comparisons between anti-hypotensive medications and current suggestions for the main indications of each medication are discussed.

show abstract

Section: Vasopressin and Terlipressinmentioning

confidence: 99%

An Update on Pharmacologic Management of Neonatal Hypotension: When, Why, and Which Medication

Agakidou,

Chatziioannidis,

Kontou

et al. 2024

Children

View full text Add to dashboard Cite

show abstract

Vasopressin, protein metabolism, and water conservation

Carty,

Watts,

Arroyo

2024

Current Opinion in Nephrology &Amp; Hypertension

Self Cite

View full text Add to dashboard Cite

Purpose of Review Highlight the mechanisms through which vasopressin and hypertonic stress regulate protein metabolism Recent Findings Mammals have an ‘aestivation-like’ response in which hypertonic stress increases muscle catabolism and urea production Vasopressin can directly regulate ureagenesis in the liver and the kidney In humans chronic hypertonic stress is associated with premature aging, diabetes, cardiovascular disease, and premature mortality Summary There is an evolutionarily conserved ‘aestivation-like’ response in humans in which hypertonic stress results in activation of the vasopressin system, muscle catabolism, and ureagenesis in order to promote water conservation.

show abstract

Rethinking Vasopressin: New Insights into Vasopressin Signaling and Its Implications

Cited by 2 publications

References 84 publications

An Update on Pharmacologic Management of Neonatal Hypotension: When, Why, and Which Medication

An Update on Pharmacologic Management of Neonatal Hypotension: When, Why, and Which Medication

Vasopressin, protein metabolism, and water conservation

Contact Info

Product

Resources

About